Abstracts tagged "SLE"

Abstract Number: 41 • 2013 ACR/ARHP Annual Meeting
Targeting Cereblon With The High Affinity Immunomodulatory Compound CC-220: A Novel Therapeutic Agent For Autoimmunity
Peter Schafer¹, Emily Rychak², Derek Mendy³, Stacey Parton¹, Lori Capone⁴, Antonia Lopez-Girona², Dorota Cedzik⁵, Jolanta Kosek⁵, Ling-Hua Zhang⁵ and Rajesh Chopra⁵, ¹Department of Translational Development, Celgene Corporation, Summit, NJ, ²Molecular & Medical Science, Celgene Signal Research, San Diego, CA, ³Celgene Signal Research, San Diego, CA, ⁴Celgene Corporation, Summit, NJ, ⁵Translational Development, Celgene Corporation, Summit, NJ
Background/Purpose: Cereblon (CRBN) is a component of the E3 ubiquitin ligase complex including CUL4A, DDB1, and ROC-1. CC-220 is a novel immunomodulatory compound currently in…
Abstract Number: 2894 • 2013 ACR/ARHP Annual Meeting
Triggering Receptor Expressed on Myeloid Cells 1 In Systemic Lupus Erythematosus
Laurie Davis¹, Yong Du², Tianfu Wu³ and Chandra Mohan⁴, ¹Internal Medicine, UT Southwestern Medical Center, Dallas, TX, ²Internal Medicine - Rheumatic Diseases, University of Texas, Southwestern Medical Center at Dallas, Dallas, TX, ³Division of Rheumatology/Internal Medicine, University of Texas, Southwestern Medical Center at Dallas, Dallas, TX, ⁴University of Houston, Houston, TX
Background/Purpose: In healthy individuals, TREM-1 proteins are cell surface receptors expressed by hematopoietic cells of the myeloid lineage. TREM-1 is a potent amplifier of proinflammatory…
Abstract Number: 1699 • 2013 ACR/ARHP Annual Meeting
Development Of Systemic Lupus Erythamatosus Among “Possible Systemic Lupus Erythamatosus ” Patients Seen In Consultation: Long-Term Follow-Up
May Al Daabil¹, Bonnie L. Bermas¹, Tabatha Norton¹, Hsun Tsao¹, Patricia Ho¹, Joseph F. Merola¹, Peter H. Schur¹, Elena M. Massarotti¹ and Karen H. Costenbader², ¹Rheumatology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ²Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA
Background/Purpose: Rheumatology consultation to rule out SLE is common. However, in a substantial proportion of patients, SLE can be neither confirmed nor ruled out at…
Abstract Number: 1567 • 2013 ACR/ARHP Annual Meeting
Desensitization To Trimethoprim/Sulfamethoxazole In Systemic Lupus Erythematosus Patients : A Retrospective Cohort Study
Yasuhiro Suyama¹, Mitsumasa Kishimoto¹, Hiroto Nakano², Chisun Min³, Yoichiro Haji¹, Ryo Rokutanda¹, Yuri Ohara¹, Hisanori Shimizu¹, Ken-ichi Yamaguchi⁴, Yukio Matsui⁴, Kazuo Matsui² and Masato Okada⁴, ¹Division of Allergy & Rheumatology, St. Luke's International Hospital, Tokyo, Japan, ²Department of Rheumatology, Kameda Medical Center, Kamogawa, Japan, ³Division of Allergy and Rheumatology, St. Luke's International Hospital, Tokyo, Japan, ⁴Immuno-Rheumatology Center, St. Luke's International Hospital, Tokyo, Japan
Background/Purpose: A high incidence of trimethoprin-sulfamethoxazole (TMP/SMX) hypersensitivity is reported in patients with systemic lupus erythematosus (SLE), and reactions are often severe. Desensitization protocol is…
Abstract Number: 636 • 2013 ACR/ARHP Annual Meeting
Neutrophil-Mediated Interferon Activation In Systemic Lupus Erythematosus Bone Marrow
Anna Bird¹, Nida Meednu², Javier Rangel-Moreno³, Srilakshmi Yalavarthi⁴, Jennifer Barnard¹, Teresa Owen⁵, Jason S. Knight⁶, Alfred Rabinovich¹, Arumugam Palanichamy², Jane Liesveld⁷, Jason W Bauer⁸, Emily Baechler⁹, Mariana J. Kaplan¹⁰ and Jennifer H. Anolik¹¹, ¹Medicine-Allergy, Immunology and Rheumatology, University of Rochester Medical Center, Rochester, NY, ²Medicine- Allergy, Immunology and Rheumatology, University of Rochester Medical Center, Rochester, NY, ³Medicine- Allergy, Immunology, and Rheumatology, University of Rochester, Rochester, NY, ⁴University of Michigan Rheumatology, Ann Arbor, MI, ⁵Medicine- Allergy, Immunology, and Rheumatology, University of Rochester Medical Center, Rochester, NY, ⁶Department of Internal Medicine, Division of Rheumatology, University of Michigan, Ann Arbor, MI, ⁷Hematology/Oncology, University of Rochester Medical Center, Rochester, NY, ⁸University of Minnesota, Minneapolis, MN, ⁹Medicine, University of Minnesota, Minneapolis, MN, ¹⁰Systemic Autoimmunity Branch, National Institutes of Health/NIAMS, Bethesda, MD, ¹¹Medicine- Allergy, Immunology and Rheumatology, University of Rochester, Rochester, NY
Background/Purpose: Although SLE is known to be associated with a type I interferon signature in the peripheral blood, the precise site and mechanism of IFN…
Abstract Number: 25 • 2013 ACR/ARHP Annual Meeting
SLE Flares Are Characterized By Generalized Polyclonal Expansions Of Antibody Secreting Cells Without Preference For Autoimmune Responses
H. Travis Ichikawa, Medicine, Emory University, Atlanta, GA
Background/Purpose: Increased circulating antibody secreting cells (ASC), including both CD138- plasmablasts and CD138+ plasma cells (PB/PC), correlate with SLE activity and are prominent during Lupus…
Abstract Number: 2796 • 2013 ACR/ARHP Annual Meeting
Effects Of BAFF Inhibition On B Cell Selection In Murine SLE
Alexis Boneparth^1,2, Ramalingam Bethunaickan³, Weiqing Huang⁴ and Anne Davidson⁴, ¹Pediatrics, The Children's Hospital at Montefiore, Bronx, NY, ²Feinstein Institute for medical Research, Manhasset, NY, ³Autoimmunity, Feinstein Institute for Medical Research, Manhasset, NY, ⁴Autoimmunity and Musculoskeletal Diseases, Feinstein Institute for Medical Research, Manhasset, NY
Background/Purpose: BAFF inhibition is a new B cell targeted therapy approved for the treatment of moderately active SLE. Although BAFF regulates selection of naïve autoreactive…
Abstract Number: 1646 • 2013 ACR/ARHP Annual Meeting
Alterations In Circulating T Follicular Helper Cells and T Regulatory Cells In Autoimmune Rheumatic Diseases Treated With B Cell Depletion Therapy: Rituximab
Pamela M.K Lutalo^1,2, Yuan Zhao², Lee Meng Choong¹, Shirish Sangle¹, Jo Spencer³ and David P. D'Cruz⁴, ¹Louise Coote Lupus Unit, St Thomas' Hospital, London, United Kingdom, ²Peter Gorer Department of Immunobiology, School of Medicine, King's College London, London, United Kingdom, ³Peter Gorer Department of Immunobiology, King's College London, School of Medicine, London, United Kingdom, ⁴Louise Coote Lupus Unit, Louise Coote Lupus Unit, St Thomas' Hospital, London, United Kingdom
Background/Purpose: Granulomatosis with polyangiitis (GPA) and systemic lupus erythematosus (SLE) are autoimmune rheumatic diseases which develop due to failure of immune self-tolerance. T follicular helper…
Abstract Number: 1571 • 2013 ACR/ARHP Annual Meeting
Efficacy Of Tacrolimus Combination Therapy During The Maintenance Phase Of Systemic Lupus Erythematosus
Kumiko Ohtsuka¹, Yusuke Miwa¹, Nao Oguro², Yoko Miura¹, Sho Ishii¹, Shinya Seki¹, Hidekazu Furuya¹, Ryo Yanai¹, Ryo Takahashi¹, Kuninobu Wakabayashi¹, Nobuyuki Yajima¹ and Tsuyoshi Kasama¹, ¹Div of Rheumatology, Showa University School of Med, Shinagawa-ku Tokyo, Japan, ²Div of Rhemuatology, Showa University School of Med, Shinagawa-ku Tokyo, Japan
Background/Purpose: In Japan, a placebo-controlled clinical trial was undertaken to investigate the efficacy and safety of tacrolimus (TAC) for lupus nephritis. Based on the results…
Abstract Number: 637 • 2013 ACR/ARHP Annual Meeting
Proteomic Approach and Validation Of Urinary Biomarkers In Lupus Nephritis
Joo Youn Lee¹, Sung Hae Chang², Hye Jin Oh³, Yong Yook Lee¹, Min Jueng Kang¹, Eun Young Lee⁴, Eun Bong Lee⁵, Eugene C. Yi¹ and Young Wook Song^1,5, ¹Department of Molecular Medicine and Biopharmaceutical Sciences, Seoul National University, Seoul, South Korea, ²Internal Medicine Rheumatology, Seoul National University Bundang Hospital, Seongnam-si, South Korea, ³Seoul National University, Seoul, South Korea, ⁴Internal medicine, Division of Rheumatology, Department of Internal Medicine, Seoul National University, Seoul, South Korea, ⁵Division of Rheumatology, Department of Internal Medicine, Seoul National University, Seoul, South Korea
Background/Purpose: Renal involvement occurs in about half of systemic lupus erythematosus (SLE) patients. A number of biochemical markers are currently used to clinically assess lupus…
Abstract Number: 31 • 2013 ACR/ARHP Annual Meeting
IgD- CD27- B Cells From Systemic Lupus Erythematous Patients Have Increased Expression Of Genes Involved In RNA Sensing and Toll-Like Receptor 3 Signaling Pathways
Scott Jenks¹, Edward Ramos² and Ignacio Sanz³, ¹Allergy, Immunology, and Rheumatology, Emory University School of Medicine, Atlanta, GA, ²Biology, Emory University, Atlanta, GA, ³Allergy, Immunology and Rheumatology, Emory University School of Medicine, Atlanta, GA
Background/Purpose: SLE patients have perturbations in B cell subsets including a large expansion of IgD-CD27- B cells (DN) in patients with active disease. Patients also…
Abstract Number: 931 • 2012 ACR/ARHP Annual Meeting
Health Care Utilization Among Medicaid Enrollees with Systemic Lupus Erythematosus Preceding the Development of End-Stage Renal Disease: Sociodemographic Variation
Candace H. Feldman¹, Linda T. Hiraki², Graciela S. Alarcon³, Jinoos Yazdany⁴, Jun Liu⁵, Michael A. Fischer⁶, Wolfgang C. Winkelmayer⁷ and Karen H. Costenbader⁸, ¹Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ²Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital/ Harvard School of Public Health, Boston, MA, ³Medicine, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, ⁴Medicine, University of California, San Francisco, San Francisco, CA, ⁵Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, Harvard Medical School, Boston, Boston, MA, ⁶Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, Boston, MA, ⁷Division of Nephrology, Stanford University School of Medicine, Stanford, CA, ⁸Rheumatology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA
Background/Purpose: Extreme sociodemographic disparities exist among systemic lupus erythematosus (SLE) patients in the development of end-stage renal disease (ESRD) from lupus nephritis. Better resource allocation…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.